Otolaryngology · 2006 · 43 citations · 14 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacologyAntimicrobial PharmacotherapyMedical MicrobiologyAcute RhinosinusitisAntimicrobial DosingAcute Bacterial Sinusitis TreatmentAcute Sinusitis ManagementBacterial Acute RhinosinusitisLevofloxacin-based TherapySafety Profile CharacterizationStreptococcus Species
OBJECTIVE: Compare two dosage strengths of levofloxacin in the treatment of acute bacterial sinusitis. STUDY DESIGN AND SETTING: Multicenter clinical trial comparing levofloxacin 750 mg for 5 days vs levofloxacin 500 mg for 10 days. RESULTS: Sinus fluid samples were obtained by antral puncture (59.2%) or by sinus endoscopy (40.8%). Among microbiologically evaluable patients, 91.4% (139/152) of patients receiving levofloxacin 750 mg achieved clinical success vs 88.6% (132/149) of patients receiving levofloxacin 500 mg (95% CI -10.0, 4.2). Clinical success rates by pathogen were above 90% in both treatment groups for the 3 typical pathogens of acute sinusitis: Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. The safety profile of the 2 dosage strengths was similar. CONCLUSION: Levofloxacin 750 mg for 5 days is noninferior to levofloxacin 500 mg for 10 days. SIGNIFICANCE: Levofloxacin 750 mg for 5 days represents a safe and effective treatment regimen for acute bacterial sinusitis. EBM RATING: A-1b.
14
Nelson L. ‘Shasha’ Jumbe, Arnold Louie, Robert Leary et al. · Journal of Clinical Investigation · 2003 · 239 citations · Full text
Nelson L. ‘Shasha’ Jumbe, Arnold Louie, Robert Leary et al. · Journal of Clinical Investigation · 2003 · 233 citations · Full text
Diagnosis and treatment of acute bacterial rhinosinusitis.
J. Lau, Deborah R. Zucker, EA Engels et al. · PubMed · 1999 · 106 citations